ALT - Altimmune, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.47
-0.18 (-3.87%)
At close: 4:00PM EDT

4.50 +0.03 (0.67%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close4.65
Open4.57
Bid4.36 x 900
Ask4.55 x 1000
Day's Range4.05 - 4.69
52 Week Range3.55 - 85.20
Volume1,235,632
Avg. Volume807,740
Market Cap30.786M
Beta (3Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-86.80
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-01-20
1y Target Est10.00
Trade prices are not sourced from all markets
  • ACCESSWIRE15 hours ago

    Today’s Research Reports on Stocks to Watch: Altimmune and MannKind

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...

  • Why Altimmune Stock Is Sliding Lower Today
    InvestorPlace9 days ago

    Why Altimmune Stock Is Sliding Lower Today

    According to Altimmune (NASDAQ:ALT), the company has entered into a purchase agreement with a several institutional investors. The common units include one common share of Altimmune stock, as well as a warrant to purchase an additional share for the same price. It also includes a warrant to purchase an additional share of ALT stock for a price of $5.39.

  • GlobeNewswire10 days ago

    Altimmune Announces $25 million Registered Direct Offering

    Each common unit is being sold at a public offering price of $5.40 and consists of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $5.40. Each pre-funded unit is being sold at a public offering price of $5.39 and consists of a pre-funded warrant to purchase one share of common stock at an exercise price of $0.01 per share and a warrant to purchase one share of common stock at an exercise price of $5.40. The public offering price of each pre-funded unit is equal to the public offering price of each common unit being sold to the public in this offering, minus $0.01.

  • GlobeNewswire15 days ago

    Altimmune Closes on $16.9 Million in Funding

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced it closed the previously announced underwritten public offering of common units and pre-funded units for gross proceeds of $12 million. Together with the Company’s registered direct offering announced on September 24, the Company received aggregate gross proceeds of $16.9 million. Altimmune intends to use the net proceeds of approximately $14.4 million from these offerings for the continued advancement of development activities for the Company’s clinical-stage product pipeline, general corporate purposes, strategic growth opportunities and repayment of the Company’s outstanding $1.5 million in aggregate principal amount of convertible notes.

  • ACCESSWIRE17 days ago

    Today’s Research Reports on Stocks to Watch: Aytu Bioscience and Altimmune

    NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Shares of Altimmune were collapsing in Friday’s session as the company announced the pricing of an underwritten public offering. Shares of Aytu Biosciences were seeing gains of over 13% despite any significant news. Aytu BioScience, Inc. shares were up 13.11% on Friday on nearly 2.8 million shares traded.

  • GlobeNewswire20 days ago

    Altimmune Announces Pricing of $12 Million Underwritten Public Offering

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the pricing of an underwritten public offering of common units and pre-funded units for a combined total of 2,400,000 units. Each common unit is being sold at a public offering price of $5.00 and consists of a share of its common stock and a warrant to purchase one share of common stock at an exercise price of $6.00.  Each warrant will be exercisable immediately and will expire five years from the date of issuance. Each pre-funded unit consists of a pre-funded warrant to purchase one share of our common stock at an exercise price of $0.01 per share and a warrant.

  • GlobeNewswire24 days ago

    Altimmune Announces $4.9 million Registered Direct Offering of Common Stock

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced it has entered into purchase agreements with several institutional investors for the purchase in a registered direct offering of 286,633 shares of its common stock at a public offering price of $17.02 per share, for expected gross proceeds of approximately $4.9 million before placement agent fees and other offering expenses payable by Altimmune. The securities described above are being offered by Altimmune pursuant to a registration statement on Form S-3 (File No. 333-217034) that was declared effective by the Securities and Exchange Commission (SEC) on April 6, 2017.  A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting Roth Capital Partners, LLC, Attention: Equity Capital Markets, 888 San Clemente Drive, Suite 400, Newport Beach, California 92660, by telephone at (800) 678-9147 or e-mail at rothecm@roth.com.

  • GlobeNewswire24 days ago

    Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development

    New funding will allow examination of mucosal immune response and additional vaccine characterization. GAITHERSBURG, Md., Sept. 24, 2018-- Altimmune, Inc., a clinical-stage immunotherapeutics company, ...

  • ACCESSWIRE28 days ago

    Today’s Research Reports on Stocks to Watch: Molecular Templates and Altimmune

    Shares of Molecular Templates were also exploding on the news that the company had entered into an agreement with Japan's Takeda Pharmaceutical Co Ltd for jointly developing CD38-targeted ETNs for treating patients with diseases such as multiple myeloma. Molecular Templates, Inc. shares closed up 52.44% on a little over 7 million shares traded yesterday. The clinical-stage oncology company was exploding on the news that it had announced an agreement with Japan's Takeda Pharmaceutical Co Ltd for jointly developing CD38-targeted ETNs for treating patients with diseases such as multiple myeloma.

  • Why Altimmune Stock Is Skyrocketing Today
    InvestorPlace28 days ago

    Why Altimmune Stock Is Skyrocketing Today

    About two weeks ago, the Gaithersburg, Maryland-based company said that its intranasal egg-free flu vaccine medication NasoVax yielded positive data from its Phase 2a study. Altimmune’s vaccine candidate also proved to elicit a considerable T cell immune response when compared to Fluzone, which is a licensed injected influenza vaccine. Altimmune also has an anthrax vaccine, as well as a cancer immunotherapeutic product in Oncosyn that it is developing at the moment.

  • GlobeNewswirelast month

    Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine

    Continued clean safety profile. An influenza specific mucosal antibody (IgA) response was demonstrated at all dose levels of NasoVAX, with the highest responses in the highest dose groups, while Fluzone and placebo groups demonstrated no response.  Mucosal antibodies can be found in tears, saliva and nasal mucous and are a first line of immune defense thereby preventing influenza infection at the site of entry in the respiratory tract.

  • GlobeNewswire2 months ago

    Altimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 Study

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced initial data from its Phase 1 study of NasoShield under investigation as a potential vaccine against anthrax.  The purpose of the Phase 1 study was to assess the safety and immunogenicity of a single intranasal dose of NasoShield at four dose cohort levels. An additional cohort received a repeated dose of NasoShield at Day 21.

  • ACCESSWIRE2 months ago

    Altimmune, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 15, 2018 / Altimmune, Inc. (NASDAQ: ALT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 15, 2018 at 8:30 AM Eastern Time. To ...

  • GlobeNewswire2 months ago

    Altimmune Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    Conference call and webcast scheduled for tomorrow, August 15, 2018, at 8:30am ET. GAITHERSBURG, Md., Aug. 14, 2018-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced financial ...

  • GlobeNewswire2 months ago

    Altimmune to Announce Second Quarter 2018 Financial Results on August 15

    GAITHERSBURG, Md., Aug. 07, 2018-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended June 30, 2018 before ...

  • ACCESSWIRE4 months ago

    Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on ALDR sign up now at www.wallstequities.com/registration. Gains were broad based as seven out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Altimmune Inc. (NASDAQ: ALT).

  • Reuters4 months ago

    U.S. hedge fund Hudson Bay to open London office - sources

    U.S. hedge fund Hudson Bay Capital is opening an office in Britain to expand its European trading book, two sources told Reuters on Tuesday. Hudson Bay, which runs $2.8 billion in assets across equity, credit and other assets, has hired a team of three for its new London base and plans to add more staff, the sources with direct knowledge of the matter said. Other U.S. hedge funds are have also increased investment in Europe, including high-profile activists such as Elliott Advisers, amid increased competition and less attractive valuations at home.

  • Reuters4 months ago

    U.S. hedge fund Hudson Bay to open London office -sources

    U.S. hedge fund Hudson Bay Capital is opening an office in Britain to expand its European trading book, two sources told Reuters on Tuesday. Hudson Bay, which runs $2.8 billion in assets across equity, credit and other assets, has hired a team of three for its new London base and plans to add more staff, the sources with direct knowledge of the matter said. Other U.S. hedge funds are have also increased investment in Europe, including high-profile activists such as Elliott Advisers, amid increased competition and less attractive valuations at home.

  • Does Altimmune Inc’s (NASDAQ:ALT) CEO Salary Reflect Performance?
    Simply Wall St.5 months ago

    Does Altimmune Inc’s (NASDAQ:ALT) CEO Salary Reflect Performance?

    Leading Altimmune Inc (NASDAQ:ALT) as the CEO, Bill Enright took the company to a valuation of US$9.21M. Understanding how CEOs are incentivised to run and grow their company is anRead More...

  • Who Are The Major Shareholders Of Altimmune Inc (NASDAQ:ALT)?
    Simply Wall St.5 months ago

    Who Are The Major Shareholders Of Altimmune Inc (NASDAQ:ALT)?

    In this article, I’m going to take a look at Altimmune Inc’s (NASDAQ:ALT) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...